Protein secretion in human mammary epithelial cells following HER1 receptor activation: Influence of HER2 and HER3 expression

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Zhang, Yi ^a,b   Gonzalez, Rachel M ^a   Zangar, Richard C ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GELATINASE A; GELATINASE B; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RANTES; UNCLASSIFIED DRUG; VASCULOTROPIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; HER2 PROTEIN, HUMAN; PROTEIN;

ARTICLE; BREAST EPITHELIUM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; GENETICS; MAMMARY GLAND; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; SECRETORY PATHWAY; TISSUE MICROARRAY;

CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SECRETORY PATHWAY; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 79851508232     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-69     Document Type: Article

References (70)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
3. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003, 284:2-13. 10.1016/S0014-4827(02)00105-2, 12648462.
4. Aaronson SA. Growth factors and cancer. Science 1991, 254:1146-1153. 10.1126/science.1659742, 1659742.
5. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001, 19:32S-40S.
6. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284:99-110. 10.1016/S0014-4827(02)00099-X, 12648469.
7. Normanno N, De LA, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De FG, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16. 10.1016/j.gene.2005.10.018, 16377102.
8. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S9-15. 10.1016/S0959-8049(01)00231-3, 11597399.
9. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001, 23:147-159. 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#, 11303632.
10. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8:307-325. 10.1634/theoncologist.8-4-307, 12897328.
11. Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs 2009, 12:302-308.
12. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001, 67:81-85. 10.1023/A:1010667108371, 11518469.
13. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61:6227-6233.
14. Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, Tanaka K, Togo S, Ohki S, Shimada H. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008, 14:2351-2356. 10.1158/1078-0432.CCR-07-4499, 18413824.
15. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008, 19:73-80. 10.1093/annonc/mdm431, 17962208.
16. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999, 59:1196-1201.
17. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, Altevogt P. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 2008, 103:1783-1797. 10.1002/jcb.21569, 17910038.
18. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:981-987. 10.1158/1055-9965.EPI-04-0404, 15824174.
19. Vazquez-Martin A, Colomer R, Menendez JA. Her-2/neu-induced "cytokine signature" in breast cancer. Adv Exp Med Biol 2008, 617:311-319. full_text, 18497054.
20. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006, 25:307-313. 10.1007/s10555-006-9000-8, 17029030.
21. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De PC, Martin M, Van Oosterom AT. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997, 76:238-243. 10.1038/bjc.1997.368, 2223937, 9231925.
22. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991, 20:11-17. 10.1007/BF01833352, 1667486.
23. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999, 5:487-491.
24. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep 1998, 5:1013-1024.
25. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92:1472-1489. 10.1093/jnci/92.18.1472, 10995803.
26. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001, 20:1594-1600. 10.1038/sj.onc.1204192, 11313906.
27. Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003, 31:1203-1208. 10.1042/BST0311203, 14641026.
28. Rodland KD, Bollinger N, Ippolito D, Opresko LK, Coffey RJ, Zangar R, Wiley HS. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008, 283:31477-31487. 10.1074/jbc.M800456200, 2581561, 18782770.
29. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10:1706-1716. 10.1158/1078-0432.CCR-0951-3, 15014023.
30. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007, 43:1117-1124. 10.1016/j.ejca.2007.01.037, 17379503.
31. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009, 11:R22. 10.1186/bcr2247, 2688951, 19400944.
32. Dong J, Opresko LK, Chrisler W, Orr G, Quesenberry RD, Lauffenburger DA, Wiley HS. The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode. Mol Biol Cell 2005, 16:2984-2998. 10.1091/mbc.E04-11-0994, 1142441, 15829568.
33. Gonzalez R, Varnum S, Zangar R. Sandwich ELISA microarrays. Generating reliable and reproducible assays for high-throughput screens. Biomarker Methods in Drug Discovery and Development 2008, 273-90. Totowa, NJ: Humana Press, Wang F.
34. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci USA 1989, 86:1249-1253. 10.1073/pnas.86.4.1249, 286665, 2919173.
35. Shankaran H, ZY, OL, Resat H. Quantifying the effects of EGFR-HER2 co-expression on HER activation and trafficking. Biochem Biophys Res Comm 2008, 2864016, 18424261.
36. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res 2003, 63:1130-1137.
37. Zhang Y, Opresko L, Shankaran H, Chrisler WB, Wiley HS, Resat H. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 2009, 10:78. 10.1186/1471-2121-10-78, 2776588, 19878579.
38. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001, 44:338-348. 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V, 11500850.
39. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, Fazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009, 18:11-21. 10.1097/PDM.0b013e31818cbdb2, 19214113.
40. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
41. Gonzalez RM, Seurynck-Servoss SL, Crowley SA, Brown M, Omenn GS, Hayes DF, Zangar RC. Development and Validation of Sandwich ELISA Microarrays with Minimal Assay Interference. J Proteome Res 2008, 7:2406-2414. 10.1021/pr700822t, 18422355.
42. Daly DS, White AM, Varnum SM, Anderson KK, Zangar RC. Evaluating concentration estimation errors in ELISA microarray experiments. BMC Bioinformatics 2005, 6:17. 10.1186/1471-2105-6-17, 549203, 15673468.
43. White AM, Daly DS, Varnum SM, Anderson KK, Bollinger N, Zangar RC. ProMAT: protein microarray analysis tool. Bioinformatics 2006, 22:1278-1279. 10.1093/bioinformatics/btl093, 16595561.
44. Zangar RC, Daly DS, White AM, Servoss SS, Tan RM, Collett JR. ProMAT Calibrator: a tool for reducing experimental bias in antibody microarrays. J Proteome Res 2009, 8:3937-3943. 10.1021/pr900247n, 19618941.
45. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
46. Jacobs JM, Mottaz HM, Yu LR, Anderson DJ, Moore RJ, Chen WN, Auberry KJ, Strittmatter EF, Monroe ME, Thrall BD, Camp DG, Smith RD. Multidimensional proteome analysis of human mammary epithelial cells. J Proteome Res 2004, 3:68-75. 10.1021/pr034062a, 14998165.
47. Kansra S, Stoll SW, Johnson JL, Elder JT. Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol Biol Cell 2004, 15:4299-4309. 10.1091/mbc.E04-03-0233, 515360, 15254267.
48. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007, 120:3688-3699. 10.1242/jcs.010488, 17895366.
49. Fan H, Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J 1999, 18:6962-6972. 10.1093/emboj/18.24.6962, 1171759, 10601018.
50. Montero JC, Yuste L, az-Rodriguez E, Esparis-Ogando A, Pandiella A. Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J 2002, 363:211-221. 10.1042/0264-6021:3630211, 1222469, 11931648.
51. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
52. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007, 24:647-656. 10.1007/s10585-007-9113-7, 17968664.
53. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166. 10.1002/ijc.10329, 11979428.
54. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4:197-250.
55. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999, 447:227-231. 10.1016/S0014-5793(99)00283-5, 10214951.
56. French AR, Tadaki DK, Niyogi SK, Lauffenburger DA. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem 1995, 270:4334-4340. 10.1074/jbc.270.9.4334, 7876195.
57. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
58. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16:797-803. 10.1097/01.cad.0000173476.67239.3b, 16096426.
59. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
60. Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998, 58:5123-5129.
61. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002, 3:125-135. 10.3816/CBC.2002.n.017, 12123536.
62. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, Garcia-Conde J, Baselga J, Clinton GM. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12:424-431. 10.1158/1078-0432.CCR-05-1807, 16428482.
63. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 2008, 314:2907-2918. 10.1016/j.yexcr.2008.07.013, 18687326.
64. Chen WN, Woodbury RL, Kathmann LE, Opresko LK, Zangar RC, Wiley HS, Thrall BD. Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor alpha. J Biol Chem 2004, 279:18488-18496. 10.1074/jbc.M310874200, 14978035.
65. Genersch E, Hayess K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 2000, 113 Pt 23:4319-4330.
66. Park MJ, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Lee YS, Lee SH, Shim BS, Kuroki T, Hong SI. Protein kinase C-alpha activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int J Oncol 2003, 22:137-143.
67. Tanimura S, Asato K, Fujishiro SH, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 2003, 304:801-806. 10.1016/S0006-291X(03)00670-3, 12727228.
68. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC. Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 2006, 207:729-734. 10.1002/jcp.20616, 16453304.
69. Stow JL, Ching LP, Offenhauser C, Sangermani D. Cytokine secretion in macrophages and other cells: Pathways and mediators. Immunobiology 2009,
70. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000, 60:5879-5886.